Authorizes pharmacists to provide opioid use disorder treatment under collaborative practice agreements.

This bill allows pharmacists in retail settings to provide opioid use disorder treatment, with collaborative practice agreements from supervising physicians. These agreements must specify the conditions under which pharmacists can prescribe controlled substances for referred patients. The bill also outlines the settings where collaborative drug therapy management is permitted, including hospitals, long-term care facilities, hospices, and ambulatory care clinics.

Authorizes pharmacists to provide opioid use disorder treatment under collaborative practice agreements.

This bill allows pharmacists in retail settings to provide opioid use disorder treatment, with collaborative practice agreements from supervising physicians. These agreements must specify the conditions under which pharmacists can prescribe controlled substances for referred patients. The bill also outlines the settings where collaborative drug therapy management is permitted, including hospitals, long-term care facilities, hospices, and ambulatory care clinics.